

1 **Evaluation of Six Commercial and Non-Commercial Colistin Resistance Diagnostics**

2 Tumisho Mmatumelo Seipei Leshaba^a, Masego Mmatli^a, Lebogang Skosana^{ab}, Nontombi

3 Marylucy Mbelle^a, John Osei Sekyere^{#acd}

4 ^a Department of Medical Microbiology, School of Medicine, University of Pretoria, South
5 Africa.

6 ^b Department of Medical Microbiology, Tshwane Academic Division, National Health
7 Laboratory Service, Pretoria, South Africa

8 ^c Department of Dermatology, School of Medicine, University of Pretoria, South Africa

9 ^d Institute of Biomarker Research, Medical Diagnostic Laboratories, Genesis Biotechnology
10 Group, Hamilton, NJ, United States

11 #Address correspondence to Dr. John Osei Sekyere, Department of Dermatology, School of
12 Medicine, University of Pretoria, 0084 Pretoria, South Africa: j.oseisekyere@up.ac.za;
13 jod14139@gmail.com

14

15 **Running head:** *Evaluation of colistin resistance diagnostic tests.*

16 **Tweet:** *“Vitek 2, Sensititre, and ComASP colistin proved superior colistin MIC tests when
17 evaluated among six tests. The Rapid NP test was comparatively efficient with a shorter
18 turnaround time, albeit with higher very major errors.”*

19

20

21

22

23 **Abstract**

24 **Background.** Resistance to colistin, a last-reserve antibiotic used for treating drug-resistant
25 infections, is increasing globally. This study evaluated six diagnostic tests designed to detect
26 colistin-resistant pathogens.

27 **Methods.** PCR and broth microdilution assays (BMD) were used to respectively characterize
28 the molecular mechanisms and phenotypic colistin resistance of 142 Gram-negative bacterial
29 isolates and controls. The sensitivity, specificity, positive- and negative-predictive values,
30 major (ME) and very major errors (VME), categorical and essential agreements (EA) of
31 ComASP Colistin, CHROMagar COL-APSE, Rapid NP Test, Sensititre, MicroScan, and
32 Vitek 2 were determined with these isolates; the BMD was used as gold standard.

33 **Results.** The Vitek 2, Sensititre, and ComASP tests were more efficient, albeit with
34 concerning ME and VMEs and low EAs. Sensititre was 100% specific with 0% ME and
35 3.61% VME; Vitek 2 had the least VME (1.25% and 0%) and a low EA (57.50%). ComASP
36 had an EA of 75.35%. MicroScan was highly sensitive (96.55%) but less specific (87.50%),
37 with very below-acceptable EAs (48.11%). The CHROMagar COL-APSE efficiently
38 identified the species with their unique colours but was the least specific (67.80%), with the
39 highest ME (32.20%) and high VME (7.23%). The Rapid NP test had the highest VME
40 (7.84%), producing results within 4 hours with 92.16% sensitivity and 96.08% specificity.

41 **Conclusion:** Vitek 2, MicroScan, ComASP colistin, and Sensititre are good for determining
42 colistin resistance; the latter two tests are recommendable for low-resourced laboratories. The
43 in-house Rapid NP test has short turnaround time with high efficiency for initial resistance
44 screening.

45 **Keywords:** colistin resistance; tests; assays; polymyxins; *Enterobacterales*.

46

47 **Introduction**

48 Increasing use of carbapenems to treat multidrug-resistant bacterial infections invariably led
49 to the adoption of colistin as a last-reserve antibiotic to counter infections that are resistant to
50 carbapenems [1–3]. Hence, bacteria that are resistant to colistin are increasingly being
51 reported worldwide [4–6]. Resistance to colistin is mediated by several molecular
52 mechanisms, including the mobile colistin resistance (*mcr*) gene, mutations in the PmrAB and
53 PhoPQ two-component systems, and mutation(s) in the MgrB regulator in *Klebsiella*
54 *pneumoniae* [1,2,4,7]. These molecular mechanisms, alongside efflux hyperexpression and
55 porin downregulation, and/or Ecr transmembrane protein mediate phenotype colistin
56 (polymyxin) resistance and heteroresistance [1,8,9].

57

58 To help clinicians easily detect and monitor colistin-resistant infections, several diagnostic
59 tests and assays, both commercial and non-commercial, have been designed and developed
60 [3,10–12]. Some of these tests (such as the BMD, ComASP™ Colistin, MicroScan, Sensititre
61 and Vitek) are mainly MIC (minimum-inhibitory concentration)-based, measuring only the
62 MICs of the isolates while others are non-MIC—based, purely providing a binary result of
63 resistant or sensitive (such as the CHROMagar COL-APSE, and Rapid NP test) [10–12]. The
64 Rapid NP test was designed to only detect colistin resistance in *Enterobacterales* and is
65 therefore not useful for all Gram-negative bacteria [10,13]. As a follow-up to previous
66 research [11], we used 142 Gram-negative isolates and controls to evaluate the performance
67 of six colistin resistance diagnostic tests: ComASP Colistin, CHROMagar COL-APSE, Rapid
68 NP test, Sensititre, Vitek 2, and the MicroScan. The BMD remains the gold standard for
69 testing colistin MICs and resistance in bacteria [10]; hence it was used as the reference
70 standard in these evaluation studies.

71

72 **METHODS**

73 **Demographics and source of clinical specimen and isolates**

74 The evaluation study was conducted on a collection of 134 Gram-negative clinical bacterial
75 (GNB) isolates including *Enterobacterales* (n=103), *Acinetobacter baumannii* (n=21) and
76 *Pseudomonas aeruginosa* (n=10) that were collected from the National Health Laboratory
77 Services, Tshwane Academic Division. Eight control strains were also included to make up to
78 142: *Escherichia coli* MC1, *E. coli* MC2, *E. coli* MC3, *Salmonella* group D MC4, *Salmonella*
79 group D MC5, *E. coli* (mcr-1) EMRC, *E. coli* ATCC 25922 (EATCC), *P. aeruginosa* ATCC
80 27853 (PATCC). Species identification was performed as part of routine laboratory testing
81 using Vitek® 2 automated system (Biomerieux, France) (Table S1). Demographic data such
82 as sex, age and sample source were retrieved from the NHLS TrakCare system (Table S1).
83 The National Food Institute, Technical University of Denmark provided five *mcr*-gene control
84 strains (four *E. coli* with *mcr-1*, *mcr-2*, *mcr-3* and *mcr-4*, as well as one *Salmonella* spp. with
85 *mcr-5*) for this study. Antimicrobial susceptibility testing also included one *Escherichia coli*
86 ATCC 25922 and one *P. aeruginosa* ATCC 27853.

87 The labels of the isolates used in this article are known to only the researchers as the original
88 labels were de-identified to maintain the patients anonymity.

89

90 **Broth Microdilution.** The reference minimum inhibitory concentration (MIC) of each isolate
91 was determined by manual broth microdilution (BMD) according to ISO standard 20776-1
92 [14]. Colistin sulfate powder (Glentham Life Sciences, England) was diluted in cation-
93 adjusted Mueller Hinton broth (CAMHB) in untreated 96-well microtiter polystyrene plates
94 (Eppendorf, Germany). Dilutions to the MIC range 128-0.25 µg/mL were established.
95 Colistin sensitivity results were interpreted according EUCAST breakpoints (susceptible
96 ≤ 2 mg/L; resistant >2 mg/L). (<https://www.nature.com/articles/s41598-020-63267-2>).

97 **Detection of *mcr*-genes.** All isolates were screened for the presence of *mcr*-1, *mcr*-2, *mcr*-3,
98 *mcr*-4 and *mcr*-5 genes using PCR. The multiplex PCR method previously described by
99 Rebelo *et al.* was used for the screening of *mcr*-genes [15]. The *mcr*-gene control strains
100 supplied by the kind courtesy of Professor Rene S. Hendriksen of the National Food Institute,
101 Technical University of Denmark, were used as positive controls.

102 **Vitek 2 system.** Besides species identification, the Vitek was also used to determine the MICs
103 of the isolates, using the manufacturer's protocols.

104 **MicroScan.** The MicroScan walkaway system (Beckman Coulter, South Africa) was used to
105 determine the sensitivity of the species to colistin using the manufacturer's protocol. Briefly,
106 an overnight culture grown on blood agar was immediately standardized using the the prompt
107 inoculation system provided in the reagent packaging for MicroScan AST (antimicrobial
108 sensitivity testing) and identification (ID) testing. The suspension was placed into the N66
109 and processed overnight in the MicroScan machine.

110 **ComASP™ Colistin.** ComASP™ Colistin by Liofilchem (Roseto degli Abruzzi, Italy) is a
111 compact panel containing freeze-dried colistin which when diluted should result in two-fold
112 dilutions ranging from 0.25-16 µg/mL [11,16]. The non-automated BMD-based assay allows
113 for four samples to be tested on a single test. The manufacturer's instructions were followed
114 to perform the ComASP™ Colistin test. A 0.5 McFarland suspension of the isolates was
115 prepared in a solution of 250 mL saline and then diluted to 1:20 in saline (Gibco, Thermo
116 Fisher Scientific, USA) to obtain solution A. Solution A (0.4 mL) was added to a tube
117 containing 3.6mL Mueller-Hinton broth provided by the ComASP™ Colistin to obtain
118 solution B. One hundred microliters of solution B were dispensed into each well and the
119 panels were incubated (Vacutec, US) at 36±2°C for 16 to 20 hours in ambient air. Results
120 were read by visually analysing the plates for turbidity.

121 **ChromAgar Col-APSE.** Fresh 24-hour culture of each isolate was dissolved in saline and
122 adjusted to 0.5 McFarland's standard. This suspension was spread on the ChromAgar Col-
123 APSE plate and incubated for 18 - 24 hours. The manufacturer's protocol was used
124 throughout this test (<https://www.nature.com/articles/s41598-020-63267-2>).

125 **Sensititre™.** Sensititre™ (Thermo Fisher Scientific, USA) "FROL" colistin-customised
126 plates were used in this study. A 0.5 McFarland standard in saline was prepared for each
127 isolate (Gibco, Thermo Fisher Scientific, USA). Ten microlitres of the 0.5 McFarland
128 suspension was transferred into an 11 mL tube containing CAMHB with TES buffer for all
129 non-intrinsic *Enterobacteriales*, *A. baumannii* and *P. aeruginosa* isolates. However, for
130 *Proteus* species, *Providencia* spp. and *Morganella morganii* 1 µL was transferred into the 11
131 mL CAMHB tube. Each Sensititre™ plate constitutes of eight rows with 12 wells, each row
132 allows for the testing of one isolate at different concentrations of colistin. Wells 1-11 contain
133 dehydrated colistin at concentrations of 0.12-128 µg/mL, respectively. Well 12 represents a
134 positive control and therefore does not contain colistin. Each well was inoculated with 50 µL
135 of the bacterial broth suspension using a manual pipette. Each plate was then covered with an
136 adhesive seal and incubated (Vacutec, US) at ± 35°C in an aerobic environment. Results were
137 read by visually analysing the plates for turbidity.

138 **In-house Rapid Polymyxin NP test.**

139 Rapid Polymyxin NP test is based on the detection of glucose metabolism related to
140 *Enterobacteriales* growth in the presence of a defined concentration of colistin [17]. The
141 formation of acid metabolites is shown by a colour change of a pH indicator (red phenol) in
142 less than 4 hours [17,18]. The rapid NP test was performed as described by Nordmann *et al*,
143 2016 [6,19–21]. To prepare the NP test solution, a 6.25g of CAMHB broth powder and
144 0.0125g of phenol red powder was added to 225 mL of distilled water. The pH of the solution
145 was then adjusted to 6.7 by adding 1-N HCL in drops after which the solution was

146 autoclaved. A 25 mL of 10% anhydrous D-glucose solution that had been sterilised by
147 filtration was added to the autoclaved CAMHB solution. Colistin stock solution (1280
148 $\mu\text{g/mL}$) was diluted to 200 $\mu\text{g/mL}$ working solution by adding 1 mL of the stock solution to
149 5.4 mL CAMHB. To make colistin-NP test solution, 100 μL of the colistin working solution
150 (200 $\mu\text{g/mL}$) was added to 3900 μL NP test solution to get a final concentration of 5 $\mu\text{g/mL}$.
151 The Rapid Polymyxin NP test was carried out in 96 well polystyrene plates (Eppendorf,
152 Germany). A 150 μL of NP test solution alone without colistin was added to wells 1, 3, 5, 7,
153 9 and 11 of each row (A-H) of the 96-well microtiter plates. Wells 2, 4, 6, 8, 10 and 12
154 contained 150 μL of colistin-NP test solution (5 $\mu\text{g/mL}$). *Proteus mirabilis* isolate from our
155 collection was used as a resistant control and *Escherichia coli* ATCC 25922 was used as a
156 susceptible control.

157 A 3.5 McFarland standard was prepared for each test isolates with sterile 0.85% NaCl
158 solution and used within 15 of preparation. Each *Enterobacterales* isolate was inoculated (50
159 μL) in parallel into the two wells, one without colistin and one with colistin. Wells H7-8 were
160 inoculated 50 μL *P. mirabilis* and wells H9-10 were inoculated with 50 μL *E. coli* ATCC
161 25922. Wells H11-12 were inoculated with 50 μL of 0.85% NaCl solution. The microtiter
162 plates were incubated for 3 h at 35 ± 2 , after 3 h of incubation, the isolates were checked for
163 change in colour every 15 minutes until 4 h of incubation. The results were read visually
164 where a change in colour of phenol red (orange to bright yellow) indicated growth.

165 **Data analysis**

166 All six antimicrobial susceptibility testing methods were compared to the ISO standard
167 20776-1 BMD. Colistin MIC results were interpreted using EUCAST's breakpoints
168 (susceptible, ≤ 2 $\mu\text{g/mL}$; resistant, >2 $\mu\text{g/mL}$). For each test, the false positives, false
169 negatives, true positives, and true negatives were determined and used for downstream
170 determination of the other performance indices (Table S1). We calculated the rates of

171 essential agreement (EA), categorical agreement (CA), very major error (VME), and major
172 error (ME) using already described methods [11]. Categorical agreement was defined as an
173 agreement in the classification of susceptible or resistant between the evaluated test and the
174 reference BMD. Essential agreement was defined as an MIC value within a 2-fold (one
175 doubling) dilution of the BMD result. A very major error occurred when the tested method
176 interpretation of an isolate was susceptible while the BMD interpretation was resistant for the
177 same isolate. A major error occurred when the investigated method's interpretation was
178 resistant, and the BMD interpretation was susceptible for the same isolate. The sensitivity and
179 specificity of each test were calculated as previously described [11].

180

181 GraphPad Prism 10 was used to calculate the odds ratio and Fisher's exact test to determine
182 the significance of each test's results against the BMD.

183

184 **RESULTS**

185 **Reference BMD.** Reference MICs of all 142 isolates were determined by standard broth
186 microdilution (BMD), either in this study or as standard protocol by the National Health
187 Laboratory Services Tshwane Academic Division. One *A. baumannii*, 51 *Enterobacterales*
188 and seven *P. aeruginosa* isolates were colistin-susceptible with BMD, including one *E. coli*
189 ATCC 25922 and a *P. aeruginosa* ATCC 27853 (Table 1). The colistin-resistant isolates by
190 BMD include 59 *Enterobacterales*, 20 *A. baumannii* and four *P. aeruginosa*. Apart from the
191 five *mcr* control strains, only two isolates, BB2 and EMRC, had *mcr-1* genes (Table 1).
192 Isolate BB2 is an *A. baumannii* with a MIC of 32 µg/mL, while isolate EMRC is an *E. coli*
193 with a MIC of 4 µg/mL. All eight intrinsically colistin-resistant *Enterobacterales* (*Proteus*
194 *mirabilis*, *Serratia marcescens*, *Morganella morganii*, *Proteus vulgaris*, *Providencia stuartii*,
195 and *Ralstonia/Burkholderia pickettii*) had MICs \geq 128 µg/mL (Table 1).

196

197 **Commercial BMD methods.** All 142 isolates were tested on ComASP™ Colistin and
198 Sensititre™. ComASP™ Colistin and Sensititre™ both had a satisfactory categorical
199 agreement of 96.48% and 97.18%, respectively. However, ComASP™ Colistin falsely
200 detected one *K. pneumoniae* (1µg/mL) and one *P. aeruginosa* (1µg/mL) as colistin-
201 susceptible isolates, resulting in 3.40% MEs. Sensititre™ accurately identified all colistin-
202 susceptible isolates. However, it failed to identify three colistin-resistant isolates, therefore
203 resulting in no MEs and 3.61% VMEs. Most isolates that were not detected by Sensititre™
204 and ComASP™ Colistin had MICs close to the breakpoints (4-8µg/mL). Only one isolate that
205 was not detected by Sensititre™ had an MIC >8 µg/mL i.e., a *K. pneumoniae* with an MIC of
206 32µg/mL. ComASP™ Colistin had an overall sensitivity and specificity of 96.39% and
207 96.61%, respectively, whereas Sensititre™ had 96.39% and 100% (Table 2).

208 Notably, ComASP™ fared better with *Enterobacterales* than with all Gram-negative bacteria
209 as its sensitivity (98.31%), specificity (98.04%), and CA (98.18%) increased while its ME
210 (1.96%) and VMEs (1.72%) reduced (Table 2): the EA, however, increased from 69.09% in
211 *Enterobacterales* to 75.35% in GNB. Sensititre's *Enterobacterales* results were comparably
212 similar to that of its GNB results (Table 2).

213 Vitek MIC results were obtained for 120 GNB and 94 *Enterobacterales*. Vitek had the highest
214 sensitivity and the second or third highest specificity among GNB and *Enterobacterales*,
215 respectively, for all the tests. It had the highest CA, the second lowest EA (after MicroScan),
216 and one of the lowest VME among the six tests (Table 2). The Microscan was equally highly
217 sensitive but less specific, with the lowest EA (46.11% and 46.91%) among all the MIC-
218 based tests. Its sensitivity was 96.55% and 100% for GNB and *Enterobacterales* respectively.
219 The MicroScan's MEs with both GNB and *Enterobacterales* (12.50% and 12.20%) were only

220 second to that of the CHROMAgar Col-APSE (Table 2) and its VMEs were 3.45% (GNB)
221 and 0% (*Enterobacterales*).

222 **CHROMAgar Col-APSE.** A total of 96/142 isolates grew on CHROMAgar Col-APSE: BMD
223 identified 19 of them as colistin susceptible, resulting in 32.20% ME and 67.80% specificity.
224 Most of the MEs (14/19) were due to *Klebsiella* spp. The chromogenic media detected most
225 colistin-resistant isolates (77/83), but it also produced a high percentage of VMEs (7.23%),
226 resulting in a sensitivity of 92.77 %. Among *Enterobacterales* alone, CHROMAgar was less
227 sensitive (91.53%) and more specific (68.63%), with fewer MEs (31.37%) and CA (80.91%)
228 than in GNB (Table 2).

229 Differentiation of the isolated bacteria by the morphological appearance of their colonies was
230 as described by the manufacturer [22]. Metallic blue (*Klebsiella*, *Enterobacter* and *Serratia*
231 spp.), cream white (*Acinetobacter*, *Salmonella* and *Pseudomonas* spp.), pink-red (*E. coli*)
232 colonies were observed (Fig. 1) [22]. Furthermore, *E. coli* could be distinguished as
233 fermenting (blue with pink borders) and non-fermenting strains (pink). Swarming was
234 observed on the *P. mirabilis*-inoculated plate because the plate was not supplemented with p-
235 nitrophenyl glycerol as recommended by Abdul Momin *et al* (2017) (Figure 1) [22].

236 **In-house Rapid NP Test.** Only 102/142 of the isolates that were *Enterobacterales* were
237 included in this test. This included 51 colistin-susceptible and 51 non-intrinsically colistin-
238 resistant *Enterobacterales* isolates. The overall sensitivity and specificity of the in-house
239 Rapid polymyxin NP test was 92.16% and 96.08% respectively. Colistin-resistant isolates
240 that were not detected include one *Salmonella* spp., two *K. pneumoniae* and one *E. coli*, with
241 MICs ranging from 4 – 128 µg/mL. Two of the false-resistant isolates, also grew on
242 CHROMAgar Col-APSE (Table S1). In this study, most results were positive within two
243 hours of incubation. Six isolates, however, were not detectable after three hours of incubation

244 but were positive after four hours. Amongst the slow-growing isolates were four *Salmonella*
245 spp., one *E. coli*, and one *E. cloacae*.

246

247 **DISCUSSION**

248 The proliferation of colistin resistance among GNB has necessitated the development of
249 better diagnostics to quickly and efficiently detect colistin-resistant organisms to control their
250 spread [1,2,4,10,11]. This study evaluated six antimicrobial susceptibility tests that were
251 developed to detect colistin-resistance with efficiency. Broth microdilution is currently the
252 golden standard for colistin susceptibility testing; however, it is considered tedious and
253 difficult [10]. Vitek 2, ComASP™ Colistin, and MicroScan had the best detection
254 (sensitivity) of colistin-resistant isolates (Table 2). When compared with Sensititre™,
255 CHROMagar Col-APSE, the Rapid Polymyxin NP test, ComASP™ Colistin, and MicroScan,
256 Vitek 2 produced the least VMEs at 1.25% and 0% for GNB and *Enterobacterales*,
257 respectively. This was followed by the MicroScan and ComASP, with VMEs of 3.45% vs
258 3.57% and 0% vs 1.96% respectively for all isolates and *Enterobacterales* (Table 2).

259

260 In essence, the Vitek 2, which is common in many well-resourced routine diagnostic
261 microbiology laboratories, is very efficient in detecting colistin resistance albeit its low EA
262 should be considered when using MICs from Vitek 2. Moreover, its initial cost, long
263 turnaround time, and skill required to operate it make it inaccessible to low-resourced
264 laboratories. Although the MicroScan is also highly sensitive with low VMEs (particularly
265 among *Enterobacterales*), its lower specificity and EA, 18 – 24-hour turnaround time,
266 operating skill required, and initial cost are also major disadvantages for low-resourced
267 laboratories [10–12]. The ComASP and Sensititre are two affordable commercial kits that can
268 be adopted in low-resourced laboratories for colistin resistance diagnosis. The Sensititre had

269 100% specificity and 72.54% vrs 71.82% EA for both GNB and *Enterobacterales*, which
270 were the best (with ComASP) among all the six tests. Hence, in terms of cost and required
271 skill, the Sensititre and ComASP are good alternatives for determining the colistin MICs and
272 resistance.

273

274 The EA recorded in this study for both commercial BMD methods is below the recommended
275 EA ($\geq 90\%$) for antimicrobial susceptibility testing systems. The EA did not improve when
276 analysing *Enterobacterales* alone for ComASP™ Colistin, MicroScan, and Sensititre™;
277 Vitek 2, however, had an increase from 57.50% (Gram-negative bacteria) to 59.78%
278 (*Enterobacterales*) (Tables 1-2). ComASP™ Colistin tended to decrease or increase the MIC
279 of a significant number of colistin-susceptible isolates (29/59) by one two-fold dilution (Table
280 S1). Notwithstanding, this observation did not change the CA between ComASP™ Colistin
281 and the reference BMD.

282

283 In this study, CHROMagar Col-APSE produced the highest rate of MEs and a high VME
284 second only to that of the in-house Rapid NP test (Tables 1-2), particularly for *Klebsiella* spp.
285 Although the specificity recorded in this study and that of Osei Sekyere *et al* (at 66,67%)
286 agree, two other studies recorded a significantly higher specificity of $\geq 97\%$ [11,22,23].
287 These discrepancies could be attributed to the different bacterial inoculum concentrations
288 used. Ali *et al* demonstrated that when a 0.5 McFarland standard inoculum was used, colistin-
289 susceptible isolates were able to grow on the media [23], whereas the same isolates were
290 inhibited when the inoculum was diluted to a density of 1×10^5 CFU/mL. Therefore, the high
291 rate of MEs in this present study could be due to the inoculum used being a 0.5 McFarland
292 standard (1.5×10^8 CFU).

293

294 The in-house Rapid Polymyxin NP test was expected to have the best performance for
295 *Enterobacterales*. Even though the test was designed specifically for colistin susceptibility
296 testing on *Enterobacterales*, its performance was inferior to that of commercial BMD
297 methods (Tables 1-2). Compared with other studies that have achieved a sensitivity of $\geq 97\%$,
298 the overall performance of the in-house Rapid Polymyxin in this study ($\sim 92\%$) is slightly
299 poor [17,18,24]. The CA of all the tests evaluated in this study except for CHROMAgar Col-
300 APSE, is within the recommended standard ($\geq 90\%$) for antimicrobial susceptibility testing
301 systems. Nevertheless, except for Vitek 2 for all GNB and MicroScan in only
302 *Enterobacterales*, all the other evaluated tests had an unacceptable VME rate of $\geq 1.5\%$.
303 Only Sensititre™ had an acceptable rate of MEs when all isolates were considered, but
304 ComASP™ Colistin's ME improved when only *Enterobacterales* were examined.

305

306 Therefore, for low-resourced laboratories and research institutions, the in-house Rapid NP
307 test is a better option in terms of turnaround time, cost, and efficiency than the CHROMAgar
308 COL-APSE, except that the latter has advantages of easy use and species identification
309 through its chromogenic compounds. In terms of cost and turnaround time, the CHROMAgar
310 is comparable to the two other commercial MIC tests: Sensititre and ComASP. Nevertheless,
311 the higher efficiency of the former two and their ability to provide actual MICs make them
312 recommendable. Yet, CHROMAgar is easier to use than these two MIC tests and the MICs of
313 ComASP should be used with caution among *Enterobacterales* owing to its 75.35% EA.

314

315 The statistical odd ratio and *p*-values metrics indicate that the tests, specifically the Vitek 2,
316 Sensititre™, ComASP™ Colistin, MicroScan, and the in-house Rapid NP test, have a
317 relatively high level of performance in identifying both resistant and sensitive isolates among
318 GNB. The PPV and NPV suggest that the tests' predictive values are highly reliable. The

319 odds ratio suggests a very strong association between the test results and the resistance being
320 tested for, indicating that the likelihood of detecting resistant isolates is significantly higher
321 when they are truly resistant, as compared to when they are not. The extremely low p-value
322 indicates that this finding is statistically significant, meaning there's a very small chance that
323 these results could have occurred by random variation alone.

324 **CONCLUSION**

325 This study discovered that commercial BMD methods had the best overall performance. In
326 the absence of resources to purchase the Vitek 2 or the MicroScan, we recommend the
327 ComASP™ Colistin and Sensititre™ as potential alternative MIC tests for routine colistin
328 antimicrobial susceptibility testing in clinical laboratories. However, isolates with MICs close
329 to the breakpoint may be misinterpreted by commercial BMD tests. As the in-house Rapid
330 NP test had the quickest turnaround time, we recommend it for colistin susceptibility testing
331 on *Enterobacteriales*, particularly in laboratories with limited resources and labour skill.
332 Notably, CHROMAgar Col-APSE produced the most errors; with colistin being a last-reserve
333 antibiotic, minimal error is critical. Hence, the use of CHROMAgar Col-APSE should be
334 validated further, possibly with lower inoculum. Notably, all the tests were able to detect
335 colistin resistance in *mcr*-positive strains.

336

337 **Acknowledgements:** We are grateful to the staff of the NHLS-TAD for their support and
338 assistance in collecting and plating the isolates. We hereby regretfully report the death of our
339 colleague Professor Nontombi Marylucy Mbelle, who died during the course of this
340 investigation. This work is dedicated to her memory. We are ever grateful to Professor Rene
341 S. Hendriksen, Ana Rita Bastos Rebelo, and Troels Ronco of the National Food Institute,
342 Technical University of Denmark, for their donation of the *mcr-1* to *mcr-5* positive controls.

343 **Funding:** This work was funded by a grant from the National Health Laboratory Service
344 (NHLS) given to Dr. John Osei Sekyere under grant number GRANT004 94807 and
345 GRANT004 94808.

346 **Transparency declaration:** The authors declare no conflict of interest.

347 **Author contributions:** TMSL undertook the laboratory investigations, undertook initial
348 analysis of the data and drafted the manuscript. MM assisted with the laboratory work.
349 BLS assisted with isolates collection and plating. NMM co-supervised the study. JOS
350 designed and supervised the study, undertook data analysis, and wrote the manuscript.
351 All authors reviewed the final version of the manuscript.


352 **Ethical approval:** The study was approved by the Research Ethics Committee, Faculty of
353 Health Sciences, University of Pretoria, under reference number 550/2020. The study
354 complied with the ICH-GCP guidelines and the Helsinki declaration.

355 **References**

- 356 [1] Mmatli M, Mbelle NM, Maningi NE, Osei Sekyere J. Emerging Transcriptional and Genomic
357 Mechanisms Mediating Carbapenem and Polymyxin Resistance in Enterobacteriaceae: a Systematic
358 Review of Current Reports. *MSystems* 2020;5. <https://doi.org/10.1128/mSystems.00783-20>.
- 359 [2] Mmatli M, Mbelle NM, Osei Sekyere J. Global epidemiology, genetic environment, risk factors and
360 therapeutic prospects of mcr genes: A current and emerging update. *Front Cell Infect Microbiol* 2022;12.
361 <https://doi.org/10.3389/fcimb.2022.941358>.
- 362 [3] Mmatli M, Leshaba TMS, Skosana LB, Mbelle NM, Osei Sekyere J. Molecular Screening of Clinical
363 Multidrug-Resistant Gram-Negative Bacteria Shows Endemicity of Carbapenemases, Coexistence of
364 Multiple Carbapenemases, and Rarity of mcr in South Africa. *Microb Drug Resist* 2022;28:1028–36.
365 <https://doi.org/10.1089/MDR.2022.0112>.
- 366 [4] Ramaloko WT, Osei Sekyere J. Phylogenomics, epigenomics, virulome and mobilome of Gram-negative
367 bacteria co-resistant to carbapenems and polymyxins: a One Health systematic review and meta-
368 analyses. *Environ Microbiol* 2022;24:1518–42. <https://doi.org/10.1111/1462-2920.15930>.
- 369 [5] Lowe M, Shuping L, Perovic O. Carbapenem-resistant Enterobacterales in patients with bacteraemia at
370 tertiary academic hospitals in South Africa, 2019 - 2020: An update. *South African Med J*
371 2022;112:545–52. <https://doi.org/10.7196/SAMJ.2022.V112I8.16351>.
- 372 [6] Jayol A, Dubois V, Poirel L, Nordmann P. Rapid Detection of Polymyxin-Resistant Enterobacteriaceae
373 from Blood Cultures. *J Clin Microbiol* 2016;54:2273–7. <https://doi.org/10.1128/JCM.00918-16>.
- 374 [7] Osei Sekyere J, Reta MA, Fourie PB. Risk factors for, and molecular epidemiology and clinical
375 outcomes of, carbapenem- and polymyxin-resistant Gram-negative bacterial infections in pregnant
376 women, infants, and toddlers: a systematic review and meta-analyses. *Ann N Y Acad Sci* 2021:1–18.
377 <https://doi.org/10.1111/nyas.14650>.


- 378 [8] Halaby T, Kucukkose E, Janssen AB, Rogers MRC, Doorduijn DJ, van der Zanden AGM, et al.
379 Genomic Characterization of Colistin Heteroresistance in *Klebsiella pneumoniae* during a Nosocomial
380 Outbreak. *Antimicrob Agents Chemother* 2016;60:6837–43. <https://doi.org/10.1128/AAC.01344-16>.
- 381 [9] Poirel L, Jayol A, Nordmann P. Polymyxins: Antibacterial Activity, Susceptibility Testing, and
382 Resistance Mechanisms Encoded by Plasmids or Chromosomes. *Clin Microbiol Rev* 2017;30:557–96.
383 <https://doi.org/10.1128/CMR.00064-16>.
- 384 [10] Leshaba TMS, Mbelle NM, Osei Sekyere J. Current and emerging polymyxin resistance diagnostics: a
385 systematic review of established and novel detection methods. *J Appl Microbiol* 2021:jam.15184.
386 <https://doi.org/10.1111/jam.15184>.
- 387 [11] Osei Sekyere J, Sephofane AK, Mbelle NM. Comparative Evaluation of CHROMagar COL-APSE,
388 MicroScan Walkaway, ComASP Colistin, and Colistin MAC Test in Detecting Colistin-resistant Gram-
389 Negative Bacteria. *Sci Rep* 2020;10:1–13. <https://doi.org/10.1038/s41598-020-63267-2>.
- 390 [12] Osei Sekyere J. Mcr colistin resistance gene: a systematic review of current diagnostics and detection
391 methods. *Microbiologyopen* 2019;8:e00682. <https://doi.org/10.1002/mbo3.682>.
- 392 [13] Jayol A, Nordmann P, Lehours P, Poirel L, Dubois V. Comparison of methods for detection of plasmid-
393 mediated and chromosomally encoded colistin resistance in Enterobacteriaceae. *Clin Microbiol Infect*
394 2017;pii:S1198-30291–4. <https://doi.org/10.1016/j.cmi.2017.06.002>.
- 395 [14] International Organization for Standardization. Susceptibility testing of infectious agents and evaluation
396 of performance of antimicrobial susceptibility test devices - Part 1: Broth micro-dilution reference
397 method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobi. *Biol Eval*
398 *Med Devices* 2019;19. <https://www.iso.org/obp/ui/#iso:std:iso:20776:-1:ed-2:v2:en> (accessed March 19,
399 2024).
- 400 [15] Rebelo AR, Bortolaia V, Kjeldgaard JS, Pedersen SK, Leekitcharoenphon P, Hansen IM, et al. Multiplex
401 PCR for detection of plasmid-mediated colistin resistance determinants, mcr-1, mcr-2, mcr-3, mcr-4 and
402 mcr-5 for surveillance purposes. *Euro Surveill Bull Eur Sur Les Mal Transm = Eur Commun Dis Bull*
403 2018;23. <https://doi.org/10.2807/1560-7917.ES.2018.23.6.17-00672>.
- 404 [16] Carretto E, Brovarone F, Russello G, Nardini P, El-Bouseary MM, Aboklaish AF, et al. Clinical
405 validation of SensiTest colistin, a broth microdilution-based method to evaluate colistin MICs. *J Clin*
406 *Microbiol* 2018;56. <https://doi.org/10.1128/JCM.01523-17>.
- 407 [17] Nordmann P, Jayol AAAA, Poirel L. Rapid Detection of Polymyxin Resistance in Enterobacteriaceae.
408 *Emerg Infect Dis* 2016;22:1038–43. <https://doi.org/10.3201/eid2206.151840>.
- 409 [18] Mitton B, Kingsburgh C, Kock MM, Mbelle NM, Strydom K. Evaluation of an In-House Colistin NP
410 Test for Use in Resource-Limited Settings. *J Clin Microbiol* 2019;57.
411 <https://doi.org/10.1128/JCM.00501-19>.
- 412 [19] Poirel L, Larpin Y, Dobias J, Stephan R, Decousser J-W, Madec J-Y, et al. Rapid Polymyxin NP test for
413 the detection of polymyxin resistance mediated by the mcr-1/mcr-2 genes. *Diagn Microbiol Infect Dis*
414 2017;90:7–10. <https://doi.org/10.1016/j.diagmicrobio.2017.09.012>.
- 415 [20] Jayol AAA, Kieffer N, Poirel L, Guerin F, Guneser D, Cattoir V, et al. Evaluation of the Rapid
416 Polymyxin NP test and its industrial version for the detection of polymyxin-resistant Enterobacteriaceae.
417 *Diagn Microbiol Infect Dis* 2018;92:90–4. <https://doi.org/10.1016/j.diagmicrobio.2018.05.006>.
- 418 [21] Nordmann P, Assouvie L, Prod'Hom G, Poirel L, Greub G. Screening of plasmid-mediated MCR-1
419 colistin-resistance from bacteremia. *Eur J Clin Microbiol Infect Dis* 2016;35:1891–2.
420 <https://doi.org/10.1007/s10096-016-2739-0>.
- 421 [22] Abdul Momin MHF, Bean DC, Hendriksen RS, Haenni M, Phee LM, Wareham DW. CHROMagar
422 COL-APSE: a selective bacterial culture medium for the isolation and differentiation of colistin-resistant
423 Gram-negative pathogens. *J Med Microbiol* 2017;66:1554–61. <https://doi.org/10.1099/jmm.0.000602>.

- 424 [23] Ali S, Hussain W, Ahmed F, Afzal RK, Mirza I, Khurshid U. Chromagar™ Col-Apse for Detection of
425 Colistin Resistance in Clinical Isolates of Multidrug Resistant Gram Negative Bacilli. J Coll Physicians
426 Surg Pak 2022;32:177–80. <https://doi.org/10.29271/JCPSP.2022.02.177>.
- 427 [24] Germ J, Seme K, Cerar T, Krizan Hergouth V, Pirs M. Evaluation of two rapid phenotypical tests-Alifax
428 rapid AST colistin test and Rapid Polymyxin NP test-for detection of colistin resistance in
429 Enterobacterales. Eur J Clin Microbiol Infect Dis 2021;40:1749–53. <https://doi.org/10.1007/S10096-021-04182-W>.
- 430




431
432 **Figure 1. Appearance of different bacterial species on the CHROMAgar-colAPSE chromogenic media. (A)** Bacterial
433 growth on CHROMAgar Col-APSE showing different colony colours. **(B)** Swarming by *P. mirabilis* on CHROMAgar Col-
434 APSE

435
436 **Table S1.** Demographics, species, complete antibiotic resistance results data, and minimum inhibitory concentrations (MICs)
437 of the isolates used in this study.



A



B

